Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erdafitinib in Patients With Advanced Solid Tumors With <i>FGFR</i> Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.

JCO precision oncology·2026
Same author

Predicting survival of patients treated with antibody-drug conjugates in early-phase clinical trials using AI-quantified 3D body composition on CT scans.

Frontiers in oncology·2026
Same author

Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort E.

European urology oncology·2026
Same author

Association between parenthood and survival among 30,386 patients hospitalized with COVID-19.

PloS one·2026
Same author

Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.

Journal of neuro-oncology·2026

Related Experiment Videos

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Adolfo González-Serrano1,2,3, Charline Jean3,4, Capucine Baldini5

  • 1Department of Urology, Hospital Universitari Son Espases, 07120, Palma, Spain.

Drugs & Aging
|June 29, 2026
PubMed
Summary

Real-world data (RWD) can supplement randomized clinical trials (RCTs) for older cancer patients. Rigorous analysis of RWD provides valuable insights into geriatric oncology treatment, safety, and outcomes, improving personalized care.

Related Experiment Videos

Area of Science:

  • Geriatric Oncology
  • Real-World Data (RWD)
  • Clinical Decision Making

Background:

  • Older adults constitute the majority of cancer patients globally but are underrepresented in clinical trials.
  • This underrepresentation limits evidence for guiding treatment decisions in this growing demographic.
  • Real-world data (RWD) from clinical practice offers a complementary data source.

Purpose of the Study:

  • To review the benefits, limitations, and considerations of using RWD in geriatric oncology.
  • To explore how RWD can inform clinical decision-making for older adults with cancer.
  • To synthesize current knowledge on leveraging RWD for improved patient care.

Main Methods:

  • Narrative review of existing literature and data sources.
  • Synthesis of potential benefits and challenges of RWD utilization.
  • Exploration of RWD applications in geriatric oncology.

Main Results:

  • RWD captures patient heterogeneity, treatment patterns, safety, effectiveness, and patient-centered outcomes.
  • RWD is valuable for assessing multidimensional health profiles beyond age, including comorbidities and functional status.
  • Challenges include data quality, standardization, bias, ethical concerns, and integration into clinical practice.

Conclusions:

  • Rigorous analysis of RWD can generate real-world evidence (RWE) to fill evidence gaps in geriatric oncology.
  • RWD can support personalized treatment strategies and improve care for older adults with cancer.
  • Advances in AI, data networks, and regulatory acceptance may enhance RWD's role.